Skip to main content
OpenTrials
Completed

NCT Number: NCT01373840

Role of Dopamine Receptors in Primary Focal Dystonias

Dystonia is a disabling movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures that may afflict 250,000 people in the U.S. While the pathophysiology of dystonia remains uncertain the treatment is rather rudimentary. A better understanding of neural mechanisms of dystonias is not only an invaluable prerequisite for developing better treatment options but also a step toward better understanding of the complex network of basal ganglia. In this study I will investigate if there is any difference between the dopamine receptors and dopamine in people with dystonia and healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Central Nervous System Diseases Dyskinesias Dystonia Dystonic Disorders Focal Dystonias Movement Disorders Nervous System Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Washington University

St Louis, Missouri, 63141, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >20
  • Male or Female
  • Any race or ethnicity
  • Primary focal dystonia (arm or cranial)
  • Ability to give informed consent

Exclusion criteria

  • Family history of dystonia
  • Pregnancy (confirmed with negative urine pregnancy test in women of child bearing potential), breastfeeding
  • Exposure to radiation therapy
  • Any MRI contraindications such as foreign metallic implants, pacemaker, and aneurysm clip etc.
  • History of cardiac disease, uncontrolled hypertension, abnormal EKG during screening phase
  • History of exposure to any drugs affecting dopaminergic systems within the last 6 months (e.g. dopamine receptor blocking agents, cocaine, amphetamine, tetrabenazine, reserpine, L-dopa, dopamine agonists, as they might affect the dopamine receptor binding or endogenous dopamine).
  • Active depression (Beck Depression Inventory_II >14)
  • Cognitive impairment (Mini-Mental State Score <27)
  • CNS active medications such as gabapentin or narcotics, muscle relaxants which might be given for pain in the 3 days prior to study
  • History of stroke, seizure, cerebral palsy, generalized dystonia, parkinsonism, inability to hold head still during the scanning time.

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

Registry information

Important dates

Study start
2011
Primary completion
2016
Study completion
2016
First posted
Jun 15, 2011
Registry last updated
May 15, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.